Randomized, Double-Blind Study of Sonidegib (Lde225) in Patients (Pts) with Advanced Basal Cell Carcinoma (Bcc)
Reinhard Dummer(University Hospital of Zurich), Michael R. Migden(The University of Texas MD Anderson Cancer Center), Karl D. Lewis(University of Colorado Denver), Ragini R. Kudchadkar, Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Uwe Trefzer(Goethe University Frankfurt), R. Herd(Glasgow Royal Infirmary), Anne Lynn S. Chang(Stanford University), Ruth Plummer(National Health Service), Dalila Sellami(Daiichi Sankyo (United States)), P. Combemale(Centre Léon Bérard), Alex Guminski(The University of Sydney), Luc Dirix(European Organisation for Research and Treatment of Cancer), Carmen Loquai(Johannes Gutenberg University Mainz), Tingting Yi(Army Medical University), John T. Lear(Salford Royal Hospital), Martin Kaatz(SRH Wald-Klinikum Gera), Alexander Stratigos(National and Kapodistrian University of Athens), H.‐J. Schulze(Siemens (Germany)), F. Cornélis(Memorial Sloan Kettering Cancer Center)
Cited by 2
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k